Ansell has settled a dispute with a Perth cosmetic clinic over its proposed registration of the trade mark ‘SKYN Love The Skyn You’re In’, after the Australian rubber latex manufacturer argued it was substantially identical to four of its condom trade marks.
Merck Sharp & Dohme has claimed ownership of a Pfizer patent related to the blockbuster Prevnar 13 vaccine, after a doctor who moved between the pharmaceutical companies and is listed as an author on the patent allegedly accessed confidential Merck documents before jumping ship to Pfizer.
A judge overseeing the pelvic mesh class action against Johnson & Johnson subsidiary Ethicon has questioned why three doctor’s professional bodies tried to negotiate court orders requiring them to hand over their member lists, agreeing the supboena was “not a garden party invitation”.
A court has barred US drug company Merck Sharp & Dohme from denying that an agreement made with German pharmaceutical company Merck KGaA was governed by German law, settling a key question before a trade mark case between the two drug giants goes to trial.
Slater & Gordon is probing a possible class action against Allergan Australia on behalf of women who developed a rare form of lymphoma linked to the company’s textured breast implants.
NSW Health is facing a potential class action alleging it underpaid junior medical officers who were denied wages for unscheduled or non-rostered hours worked.
Slater & Gordon has filed a class action against life sciences giant Bayer over allegedly defective contraceptive implants that caused serious side effects, requiring many patients fitted with the devices to have hysterectomies.
The former CEO and director of biotech company Sirtex Medical, Gilman Wong, is facing a maximum ten years in prison after pleading guilty to insider trading.
Country Care Group has criticised the DPP for the “argumentative” tone of the notice setting out its criminal cartel case against the mobility equipment provider, and has secured an order for further clarity from prosecutors.
Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.